Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crestor for Palliative Treatment of Hepatocellular Carcinoma
NCT02785874Terminated
- Sponsor
- Taipei Medical University WanFang Hospital
- Start
- Sep 2016
- Primary completion
- Oct 2016
- Countries
- 1
01
Overview
Randomised, open-label trial of rosuvastatin in hepatocellular carcinoma (HCC), sponsored by Taipei Medical University WanFang Hospital. Primary endpoint: Overall Survival at 2 years. Started Sep 2016; status: terminated.
02
Drugs
rosuvastatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02785874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02785874.